A phase II study of TAS-102 plus Bevacizumab therapy for advanced/recurrent colorectal cancer with difficulty on intensive chemotherapy

Phase 2

• Conditions: Colorectal Cancer

• Registration Number: JPRN-UMIN000022705
• Lead Sponsor: Osaka medical Center for Cancer and Cardiovascular Diseases

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-06-12
• Study Completion: 2019-03-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1) with symptoms due to brain metastatis 2) with uncontrolable diarrhea 3) with difficulty on oral intake due to intestinal paralysis or obstruction 4) with infections diseases or febrile condition 5) with severe pulmonary diseases (interstitial pneumonia, pulmonary fibrosis, pulmonary emphysema etc) 6) with severe diseases (uncontrollable DM, heart failure severe than NYHA lll, renal failure, and/or hepatic failure) 7) pregnant and/or nursing women, or women who expect pregnancy 8) with metastatic meningitis, uncontrollable convulsion, and/or mental disorder 9) with a condition intolerance to medicines in this regimen 10)with a history of some chemotherapy and/or therapy including a VEGF antagonist 11) with a history of embolism, brain infraction (except Lacuna infraction) or pulmonary infraction 12) under easy bleeding condition due to some diseases or medicines (except low dose aspirin) 13) with active wounds except reservoir surgery 14) with a history of bloody spit more than 2.5ml 15) with no bowel obstruction 16) with no peritoneum disseimination 17) any other patient whom the physician in charge of the study judges to be unsuitabl

Study & Design

• Study Type: Interventional
• Study Design: Not specified